Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $113 to $116.
November 09, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Ascendis Pharma and raises the price target from $113 to $116, which could potentially influence the stock's performance.
The raised price target by Morgan Stanley indicates a positive outlook for Ascendis Pharma. This could potentially lead to an increase in the stock's price in the short term as it suggests that the analyst believes the stock is undervalued at its current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100